Danaher Corporation $DHR Shares Acquired by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp increased its holdings in Danaher Corporation by 5.3%, acquiring an additional 2,657 shares, bringing their total ownership to 52,859 shares valued at $10.84 million.
• Insider trading activity includes Director Teri List selling 2,778 shares at an average price of $211.06, reducing their holdings by 11.81%.
• Danaher reported a net margin of 14.21% and beat earnings estimates with $1.80 earnings per share for the last quarter, also setting a fiscal year 2025 EPS guidance between 7.700-7.800.

OMERS ADMINISTRATION Corp grew its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 5.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,859 shares of the conglomerate's stock after acquiring an additional 2,657 shares during the quarter. OMERS ADMINISTRATION Corp's holdings in Danaher were worth $10,836,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Coastal Bridge Advisors LLC increased its holdings in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after acquiring an additional 50 shares in the last quarter. Hills Bank & Trust Co boosted its position in Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after buying an additional 53 shares during the last quarter. Sageworth Trust Co boosted its position in Danaher by 2.3% in the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after buying an additional 54 shares during the last quarter. 1834 Investment Advisors Co. boosted its position in Danaher by 3.3% in the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after buying an additional 54 shares during the last quarter. Finally, Rakuten Securities Inc. boosted its position in Danaher by 33.3% in the first quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after buying an additional 56 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Price Performance

NYSE:DHR traded up $0.80 during trading hours on Monday, reaching $206.09. 1,979,809 shares of the company were exchanged, compared to its average volume of 3,131,448. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock's 50-day moving average is $201.65 and its 200-day moving average is $199.46. The firm has a market cap of $147.57 billion, a PE ratio of 43.85, a price-to-earnings-growth ratio of 2.87 and a beta of 0.75. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DHR. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. UBS Group dropped their target price on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research report on Wednesday, July 23rd. Wells Fargo & Company lowered their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. Finally, Robert W. Baird upped their price objective on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average price target of $247.61.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 11.20% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.